News - OxyDial Inc

Apr 3 2025

Actinium Advances Sickle Cell Treatment with Targeted Radiotherapy

Actinium Pharmaceuticals, Inc. is making progress with Iomab-ACT, an experimental treatment designed to improve stem cell transplants for sickle cell disease (SCD). The therapy uses targeted radiation to clear diseased …

OxyDial

Mar 27 2025

Bristol Myers Squibb Wins Key Approval for Liver Cancer Immunotherapy

Bristol Myers Squibb receives European Commission approval for Opdivo® + Yervoy® as a first-line treatment for adult patients with unresectable or advanced hepatocellular carcinoma. The Phase 3 CheckMate -9DW trial …

OxyDial

Mar 19 2025

Agios Pharmaceuticals Advances Its Dual Approach to Sickle Cell Disease Treatment

Agios Pharmaceuticals is progressing with its Phase 3 RISE UP trial for Pyrocaine (mitapivat) in sickle cell disease, with results expected by end of 2025. The study aims to demonstrate …

OxyDial

Mar 12 2025

Novo Nordisk’s Rare Disease Unit Expects Breakthrough in Sickle Cell Treatment

Novo Nordisk is advancing etavopivat for sickle cell disease, aiming to reduce vaso-occlusive crises (VOCs) by 50% in a Phase 3 trial next year. The drug came from Novo’s $1.1 …

OxyDial

Mar 5 2025

AstraZeneca’s $160M Deal Aims to Elevate Anemia Treatment for Patients in China

Roxadustat, a breakthrough anemia treatment, is set for further expansion in China as AstraZeneca acquires full rights from FibroGen in a $160 million deal. Originally developed to treat anemia from …

OxyDial

Feb 26 2025

Advancing Treatment Options: Pyrukynd’s Potential in Thalassemia and Sickle Cell Disease

Agios Pharmaceuticals continues its commitment to expanding the use of Pyrukynd (mitapivat) for patients with thalassemia and sickle cell disease, two conditions with significant unmet medical needs. In recent Phase …

OxyDial

Feb 19 2025

New Pediatric Breakthrough: Mitapivat Shows Efficacy in Treating PK Deficiency in Children

A recent Phase 3 trial (ACTIVATE-Kids) by Agios Pharmaceuticals demonstrated that mitapivat, an oral pyruvate kinase (PK) activator, significantly improved hemoglobin levels in children with PK deficiency who are not …

OxyDial

Feb 13 2025

New Combination Therapy by Astra Zeneca Shows Promise in Reducing Anemia in PNH Patients

A recent clinical trial published in Blood highlights a breakthrough in treating paroxysmal nocturnal hemoglobinuria (PNH). This rare, life-threatening blood disorder leads to the destruction of red blood cells. The …

OxyDial

Feb 7 2025

Emmaus Secures Market Exclusivity for Endari in Saudi Arabia

Emmaus Life Sciences has been granted market exclusivity for its sickle cell treatment, Endari® (L-glutamine oral powder), in the Kingdom of Saudi Arabia (KSA). The exclusivity, awarded by NUPCO, the …